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ABSTRACT
Introduction: Androgen decline in the aging man has become a topic of increasing clinical relevance worldwide, as the 
reduction in testosterone levels has been reported to be accompanied by loss of muscle mass, accumulation of central 
adiposity, impaired mobility and increase risk of bone fractures. Although well-established in studies conducted in 
developed countries, progressive decline in serum testosterone levels with age has been poorly investigated in Brazil.
Aim: To determine the pattern of blood testosterone concentrations decline with age in a cohort of Brazilian healthy 
military men.
Materials and Methods: We retrospectively reviewed data on serum testosterone measurements of healthy individuals 
that had undergone a routine check-up at the Military Biology Institute. Blood samples were obtained early in the 
morning, and total testosterone concentration was determined using a commercial chemoluminescent immunoassay. 
Mean values were analyzed in five age groups: ≤ 40, 41 to 50, 51 to 60, 61 to 70, and > 70 years.
Main Outcome Measure: Mean total testosterone levels.
Results: 1,623 subjects were included in the analysis; mean age was 57 years (24 to 87), and mean testosterone level 
was 575.5 ng/dL (25.0 to 1308.0 ng/dL). The evaluation of age-related changes in total testosterone levels revealed 
a progressive reduction in serum levels of this hormone with increasing age. Testosterone levels below 300 ng/dL 
were reported in 321 participants, a prevalence of nearly 20% in the study population.
Conclusion: In agreement with other findings, a reduction of total testosterone levels with age was reported for 
healthy Brazilian men.
Key words: testosterone; male; deficiency; epidemiological studies; cohort studies
Int Braz J Urol. 2011; 37: 591-597
 Over the last decades, an increase in life 
expectancy has been observed worldwide (1). In 
addition, population projections indicate that the 
world population will experience a marked in-
crease in the proportion of individuals older than 
65 years. According to the United Nations, the per-
centage of the world’s population over 60 is ex-
pected to nearly double between 2005 and 2050 
(2). In this context, projections for the Brazilian 
population estimate an increase in the number of 
men older than 60 years, from 9 million (represent-
ing 9% of the total country population) to 30 mil-
lion (13%), between 2010 and 2020 (3). Despite 
the fact that males do not live as long as females, 
the health of aged men has been studied to a much 
lesser extent than that of postmenopausal women. 
Thus, growing attention is being devoted to health 
disorders in aging men.
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Testosterone decline in military men
 Aging in men is associated with impaired 
mobility, accumulation of central adiposity, de-
creased lean body and muscle mass, strength, and 
bone mineral density, as well as increased body 
fat (4), abnormalities that are also present in non-
elderly hypogonadal men. Unlike women, who ex-
perience a dramatic change in sex-hormone profile 
during menopause (5), age-related changes in re-
productive hormones occur gradually throughout 
the years of life in men (6,7). As the alterations 
in hormonal status are subtle, the characterization 
of age-normal endocrine profile is particularly dif-
ficult in males.
 It is well-established that after the fourth 
or fifth decade of life, men undergo a gradual shift 
in the levels of important sex hormones, with a rise 
in luteinizing hormone (LH), follicle-stimulating 
hormone (FSH), and sex-hormone-binding globu-
lin (SHBG), contrasting with a decline in testoster-
one and dehydroepiandrosterone (DHEA) (8-11). 
It has been estimated that from the age 19, circulat-
ing testosterone declines at an average rate of 1% 
per year of life, or 100 ng/dL (4,7,8).
 Several age-related phenomena such as de-
crease in muscle strength and mass, decline in viril-
ity and sexual activity, and impairment of glucose 
metabolism have been associated with a reduction 
in testicular function in aging men (12). The extent 
to which declining testosterone levels may influ-
ence age-related deteriorations is not completely 
defined. In addition, androgen deficiency in the ag-
ing male (ADAM) is characterized by the presence 
of a group of signs and symptoms and a significant 
decline in the production of hormones, most im-
portantly testosterone.
 Age-related decline in testosterone levels 
has been demonstrated by several cross-sectional 
and longitudinal studies conducted in developed 
countries (4,11). However, data on the androgen 
profile of aging men are scarce for Brazil.
Aim
 The aim of the present study was to inves-
tigate the age-related decline of total testosterone 
levels in healthy Brazilian men in military activity.
MATERIALS AND METHODS
Study design
 In this retrospective study, data on tes-
tosterone levels of healthy military subjects were 
reviewed. Blood samples were collected from 
January 2009 to September 2009 at the Military 
Biology Institute (“Instituto de Biologia do Exér-
cito” - IBEX), located in Rio de Janeiro, Brazil, as 
part of a routine health check-up that was manda-
tory for military individuals in activity or retired at 
that time. The study was designed to collect demo-
graphic and laboratory parameters of healthy men, 
age 18 or older, in activity at the military service 
or retired. All individuals with available hormone 
measurements were included.
 The patients were not on testosterone re-
placement therapy. They were not taking medica-
tions that affect testosterone level, such as clomid 
or HCG injections, nor were they taking antiandro-
gens such as cimitidine, Aldactone, etc. They had 
not undergone previous surgery e.g. orchiectomy, 
nor had they received chemotherapy or radiation on 
the testis. They did not have chronic liver disease or 
liver cell failure, nor  did they suffer from morbid 
obesity, DM, or chronic illness.
Laboratory measurements and statistical analysis
 Blood samples were obtained early in the 
morning, between 7:00 and 09:30 AM, and ana-
lyzed at the IBEX laboratory. Serum was immedi-
ately separated after blood collection and samples 
were stored at -80oC. Total testosterone level was 
measured using a commercial chemoluminescent 
immunoassay, with an analytical sensitivity of 300 
to 1000 ng/dL. Data collected from each subject 
included age and mean total testosterone levels. 
Laboratory testosterone levels compatible with 
hypogonadism were defined as < 300 ng/dL, based 
on the guidelines for ADAM of the Brazilian Soci-
ety of Urology.
 Participants’ total testosterone levels were 
used for analysis, and mean values were analyzed 
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regarding the age groups. For this purpose, subjects 
were divided in the following age groups: ≤ 40, 41 
to 50, 51 to 60, 61 to 70, and > 70 years.
RESULTS
Sample characteristics
 A total of 1623 healthy subjects were evalu-
ated in the present study. Demographic and labora-
tory data of all individuals included in the analysis 
are summarized in Table-1. The mean age was 57 
years, ranging from 24 to 87 years. Mean total tes-
tosterone level was 575.5 ng/dL, ranging from 25.0 
to 1308.0 ng/dL. Concerning the distribution of par-
ticipants according to different age groups, 13.6% 
were ≤ 40 years, whereas the majority of subjects 
were older than 50 years, as shown in Table-2.
Testosterone measurements according to age
 In order to evaluate age-related changes in 
total testosterone levels, the concentration of this 
hormone was analyzed in the different age groups, 
as shown in Figure-1. In this regard, a progressive 
reduction in serum total testosterone levels was 
observed across age groups, with the mean testos-
terone value observed for younger men (821.1 ng/
dL; age group ≤ 40 years) being almost twice as 
high as the levels found for individuals belonging 
to the older age group (436.6 ng/dL; age group > 70 
years).
 Figure-2 shows the distribution of par-
ticipants according to the mean testosterone level 
groups. Although the study sample consisted of 
apparently healthy individuals, 0.8% of the sub-
jects had testosterone levels ≤ 100 ng/dL, 3.6% 
Table 1 - Characteristics of the 1,623 participants included in the analysis.
Table 2 - Distribution of subjects according to age groups.
Characteristics Value
Age (years)
Mean 57.0
Range 24 to 87
Total testosterone levels (ng/dL)
Mean 575.5
Range 25.0 to 1308.0
Age group (years) Number of subjects (%)
≤ 40 221 (13.6)
41 to 50 312 (19.2)
51 to 60 448 (27.6)
61 to 70 512 (31.6)
> 70 130 (8.0)
Total 1623
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had mean  levels between 101 and 200 ng/dL, and 
15.9% of participants had a mean concentration of 
this hormone in the range of 201 and 300 ng/dL. 
Testosterone levels below 300 ng/dL, compatible 
with hypogonadism, were reported for 321 partici-
pants, representing a prevalence of 19.8%.
DISCUSSION
 In this study, the hormone profile of a cohort 
of healthy Brazilian men in military activity was in-
vestigated. We found, in agreement with the current 
literature, a decline in total testosterone levels associ-
ated with male aging.
 Testosterone is largely bound to plasma pro-
teins, with only 1-2% being free, 40-50% being bound 
to albumin, and the rest being strongly bound to SHBG 
(12). Plasma concentrations of this androgen show cir-
cadian variations with highest values in the morning, 
and serum free testosterone and albumin-bound tes-
tosterone represent the fractions readily available for 
biological action (13). As testosterone exerts a wide 
Figure 1 - Age groups.
Figure 2 - Testosterone level groups. (ng/ dL)
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role in male physiology, controlling gonadal function 
and altering libido, mood, aggressive behavior, liver 
function, muscle mass, bone formation, lipid metabo-
lism, erythropoiesis, and immune system, its decline 
is of particular concern in the management of men’s 
health (14).
 In men, a progressive decline in testosterone 
levels with age has been suggested in several cross-
sectional and longitudinal studies, with an average 
rate of decline of 1% to 2% per year after the age of 
40. In addition, data indicate that a significant percent-
age (20%) of men over 60 years exhibit serum levels 
below the lower limits of young men. Moreover, at the 
age of 75 years, mean total serum testosterone level 
was found to be about two-thirds of the levels at age 
25, whereas the mean values of free and bioavailable 
testosterone serum levels are only about half of those 
in young men, as demonstrated in different studies 
(4,8,15,16). In addition to changes in total testoster-
one, a decline in free and bioavailable testosterone has 
been demonstrated in cross-sectional studies.
 Morley et al. demonstrated in a longitudinal 
study, conducted in older healthy men (61 to 87 years 
at entry), that testosterone levels decline with age, with 
an average rate of decrement of 110 ng/dL for every 
decade of life. In addition, LH and FSH were found 
to increase in older men (7). Longitudinal changes in 
androgen hormones have been also reported in more 
recent studies. In this regard, using longitudinal data 
from the Massachusetts Male Aging Study (MMAS), 
which included at baseline a large cohort of men aged 
40 to 70 years. Feldman et al. reported a rate of de-
cline in total testosterone with age of 0.8% per year, 
and a declining rate of 2.0% per year for both free 
and albumin-bound testosterone. Of note, in this study 
the rate of decline was similar in apparently healthy 
men and in those reporting obesity, chronic illness, al-
coholism, prostate problems, or prescription medica-
tion (8). In another longitudinal study, Liu et al found 
that the decline in serum testosterone and increase in 
SHBG with age were comparable across two sepa-
rate regional Australian populations (11). The influ-
ence of age in the testosterone levels was confirmed 
by Clapauch et al. in a study conducted in a cohort 
of 216 Brazilian men aged 52-84 years (17). In this 
study, a significant difference in the level of total tes-
tosterone was observed between patients < 60 years 
versus those aged 70 years or more. In addition to total 
testosterone, a significant difference in free testoster-
one levels was also observed between these two age 
groups (17).
 In young patients, severe testosterone defi-
ciency (170 to 230 ng/dL) is typified by a familiar ar-
ray of symptoms, whereas in aging men, symptoms 
are non-specific and usually mimicked by other disor-
ders. In older men, the testosterone level below which 
symptoms of androgen deficiency emerge remains un-
clear (18,19).
 Adult hypogonadism can be caused by ab-
normalities of the hypothalamic-pituitary-testicular 
axis at the testicular level causing primary testicu-
lar failure, or by disturbances of the hypothalamus 
or pituitary resulting in secondary testicular impair-
ment. Adult hypogonadism is manifested by infertil-
ity, alterations in behavior, low sexual desire, erec-
tile dysfunction, depression, fatigue, loss of sense of 
well-being, and some secondary sexual characteristics 
(18,20). Obesity, severe systemic illness and medica-
tions are among the commonly acquired causes of 
adult-onset hypogonadism, and defects in both testic-
ular and hypothalamic-pituitary function may under-
lie the age-associated reductions in testosterone lev-
els demonstrated in cross-sectional and longitudinal 
studies. In our sample, testosterone levels compatible 
with hypogonadism (< 300 ng/dL) were observed in 
almost 20% of the participants. Although this concen-
tration is not diagnostic of hypogonadism per se, it 
may indicate the need of preliminary screening for 
free or bioavailable testosterone levels below refer-
ences values. Recently, Wu et al. found, in a system-
atic investigation of a large cohort of aging men from 
the general population, that late-onset hypogonadism 
can be defined by the presence of at least three sexual 
symptoms associated with a total testosterone concen-
tration lower than 11 nmol per liter (320 ng/dL) and a 
free testosterone level of less than 220 pmol per litre 
(64 pg/mL) (18).
 Although an improvement in signs and 
symptoms of testosterone deficiency in younger 
adult men is supported by some studies, the treat-
ment of testosterone deficiency in the older man is 
more controversial. Recently, an update of the guide-
lines for the evaluation and treatment of androgen 
deficiency syndromes in adult men was published, 
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recommending that the diagnosis of androgen defi-
ciency should be restricted to men with consistent 
symptoms and signs and low serum testosterone 
levels (21). In this regard, the analysis of morning 
total testosterone levels is indicated as the initial 
diagnostic test, which should be confirmed in a 
repeated measure (21). In this guideline, testoster-
one therapy is recommended for men with symp-
tomatic deficiency of androgens, aiming to main-
tain secondary sex characteristics and to improve 
sexual function, well being, and bone density, with 
the exception of patients with breast or prostate 
cancer, and other health conditions not mentioned 
here. Importantly, there is a recommendation 
against androgen deficiency screening in the gen-
eral population. Regarding the elderly population, 
for older men with consistent low testosterone 
levels and clear clinical symptoms of androgen 
deficiency, testosterone therapy should be consid-
ered by clinicians on an individualized basis, con-
sidering the risks and benefits of this therapeutic 
approach (21). The effects of testosterone admin-
istration on body composition, bone density and 
muscle strength in middle-aged men were evalu-
ated in a meta-analysis of randomized controlled 
trials. Testosterone treatment promoted reduction 
of body fat, increase in fat-free mass, with no 
change in body weight. In addition, testosterone 
also reduced total cholesterol, with no change in 
low density lipoprotein-cholesterol (22). Despite 
some good results, whether testosterone therapy is 
beneficial for aging men in preventing or delaying 
some aspects of ageing is still controversial, and 
more studies are needed (23,24).
CONCLUSIONS
 In agreement with other studies we found 
that total testosterone levels decline with age in 
healthy Brazilian men. A high prevalence of tes-
tosterone levels below 300 ng/dL, compatible with 
laboratory hypogonadism, was found in this cohort.
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